Phase 1 clinical trial of autologous dendritic cells to induce antigen-specific tolerance

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/301244

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

We have previously generated modified dendritic cells in mice with the ability to suppress immune responses once they have started. This project will develop the dendritic cell vaccine as a platform technology for human clinical use. We aim to demonstrate, in a phase I clinical trial, the capacity of modified human autologous dendritic cells to suppress the immune response to a model antigen in a group of healthy volunteers and a group of patients with rheumatoid arthritis taking drugs for their disease

Funded Activity Details

Start Date: 01-01-2004

End Date: 01-01-2004

Funding Scheme: NHMRC Development Grants

Funding Amount: $165,125.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical chemistry (incl. diagnostics)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Clinical trial | Dentritic cell | Rheumatoid arthritis | Tolerance | Vaccine

Related Links